

August 31, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
Scrip Code: 511509

Dear Sir/Madam,

Subject : Appointment of Mr. Shyam Sunder as an Additional Non-Executive Independent Director

Reference : Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

With reference to the above cited subject, and pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, (“Listing Regulations”), and based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held today, i.e. **Thursday, August 31, 2023**, transacted the following business:

1. Appointed Mr. Shyam Sunder Tipparaju (DIN: 07167885) as an Additional Director designated as Non-Executive and Independent Director for a period of (5) five years from August 31, 2023 to August 30, 2028 subject to the approval of shareholders.

Mr. Shyam Sunder Tipparaju (DIN: 07167885) will be a Non-Executive, Independent Director and he is not related to the Promoter or Promoter Group and fulfills the criteria of independence as required under the provisions of the Companies Act, 2013 and the Rules framed thereunder and the Listing Regulations.

Further, in accordance with Circular no. LIST/COMP/14/2018-19 June 20, 2018 issued by BSE Limited, Mr. Shyam Sunder Tipparaju (DIN: 07167885) is not debarred from holding the office of Director by virtue of any Securities Exchange Board of India (SEBI) order or of any other authority.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, and brief profile of Mr. Shyam Sunder Tipparaju (DIN: 07167885) is provided in “Annexure – A”.

This is for your information and records.

Thanking You,

For Vivo Bio Tech Limited

Jyotika Aasat
Company Secretary

Encl as above.

Annexure – A

Disclosure required pursuant to Regulation 30 of the Listing Regulations read with Para A of Schedule III to the Listing Regulations read with the SEBI Circular having reference no. CIR/CFD/CMD/4/2015 dated September 09, 2015, with regard to change in Directors and Key Managerial Personnel is given herein under:

S.No	Particulars	Disclosure
1	Name	Mr. Shyam Sunder Tipparaju DIN: 07167885
2	Reason for Change viz., appointment, resignation, removal, death or otherwise	Appointment of Mr. Shyam Sunder Tipparaju as an Additional Director, designated as Non-Executive and Independent Director of the Company, subject to approval of shareholders.
3	Date of appointment/cessation (as applicable) & terms of appointment	August 31, 2023 Period – 5 years
4	Brief profile (in case of appointment)	Mr. Shyam Sunder Tipparaju – “Believes in Medicine as a scientific discipline based on humanism”. He has over 30 years of quantifiable experience in Critical Care and 10 years of experience in handling Healthcare Operations of large Super Speciality Hospitals. He has been practicing Critical Care for the last 3 decades and is responsible for conceptualizing to Inceptualization of three major corporate Hospitals in Hyderabad. He is also Certified for Good Clinical Practice by NIDA Clinical Trials Network and is a Chairman – Telangana Chamber of Commerce and Industries-Medical and Health. He has completed his MBBS from Gandhi Medical College 1983, MD from NTR Medical University in 1987 and Post Doctoral Critical Care in 1993-94. He has won Legend in Critical Care Award in 2022, APJ Abdul Kalam Excellency Award in 2017, Best Teacher Award - ISCCM in 2017 and Awarded Eminent Citizen of India - Gold Medal in 1997. He has worked as Chairman – Medical Care of Galen Medicare Private Limited since 2020 to till date and previously had worked as Director of Thumbay Hospital, Hyderabad from 2015-2020 and as Medical Director of Continental Hospital Hyderabad from 2011-2015.
5	Disclosure of relationships between directors	Mr. Shyam Sunder Tipparaju is not related to any of the Directors on the Board.